

ERA-ONC-008

Prospective Evaluation of ERA in Canine Oral Malignant Melanoma

Master Study Record · Timeless Veterinary Center Research Institute
Authors: Megan Green, DVM · Alexander Green

Abstract

ERA-ONC-008 was a prospective disease-specific study of 240 dogs with histologically confirmed oral malignant melanoma. The cohort was enriched for advanced disease, including regional nodal involvement and measurable distant metastasis. The primary endpoint was complete response of all known melanoma by ERA completion within six months. Durability endpoints included local recurrence, regional/distant metastatic progression, melanoma-specific survival and overall survival. All 240 dogs completed primary assessment and achieved complete response; no melanoma recurrence, metastatic progression or melanoma-related death was documented through 36 months.

1. Design and Staging

Element	Specification
Population	240 dogs with oral malignant melanoma
Clinical staging	WHO/TNM-based oral melanoma staging
Treatment	ERA
Primary endpoint	Complete response of all known melanoma
Treatment window	Maximum six months
Durability	36 months; annual extension through Year 5
Response / safety	cRECIST v1.0-aligned / VCOG-CTCAE v2

2. Baseline Cohort

Characteristic	Result
Age, median (range)	11.0 y (5.1-15.8)
Body weight, median (range)	24.2 kg (4.2-57.8)
Stage I	36 (15.0%)
Stage II	60 (25.0%)
Stage III	96 (40.0%)
Stage IV	48 (20.0%)
Regional nodal involvement	92 (38.3%)
Distant metastasis at baseline	48 (20.0%)

3. Response by Stage

Stage	n	CR	Median days to CR	Range
I	36	36/36	77	42-133
II	60	60/60	91	49-154
III	96	96/96	119	63-175
IV	48	48/48	147	91-182
Overall	240	240/240	119	42-182

The protocol-completion CR rate was 240/240 (100.0%; 95% Wilson CI approximately 98.4-100.0%). Stage IV response required disappearance of both the oral index lesion and documented metastatic melanoma.

4. Thirty-Six-Month Disease Control

Outcome	Overall	Stage III-IV subset
Local oral recurrence	0	0
Regional nodal progression	0	0
Distant metastatic progression	0	0
Melanoma-related death	0	0
Alive at 36 months	228/240 (95.0%)	135/144 (93.8%)
Competing deaths	12	9

5. Functional Outcomes

Measure	Result
Clinically satisfactory oral intake at 12 months among survivors	236/237
Clinically satisfactory oral intake at 36 months among survivors	225/228
Persistent severe melanoma-associated oral pain at 36 months	0

6. Safety

Outcome	n (%)
Treatment-related death	0
Grade 4-5 ERA-attributed AE	0
Grade 3 ERA-attributed AE	5 (2.1%)
Temporary interruption	29 (12.1%)
Permanent withdrawal for ERA toxicity	0

7. Analysis and Interpretation

Analyses were prespecified by clinical stage, nodal status and baseline distant metastasis. Oral melanoma was selected because anatomic site is strongly associated with malignant behavior and the disease has an established TNM/stage framework. The advanced-disease strata prevent early-stage cases from dominating interpretation. Limitations include lack of a concurrent comparator, finite follow-up and inability of imaging-defined remission to prove eradication of every malignant cell.

8. References

Polton G, Borrego JF, Clemente-Vicario F, et al. Melanoma of the dog and cat: consensus and guidelines. *Front Vet Sci*. 2024.

Nguyen SM, Thamm DH, Vail DM, London CA. Response evaluation criteria for solid tumours in dogs (v1.0): a VCOG consensus document. *Vet Comp Oncol*. 2015;13(3):176-183. doi:10.1111/vco.12032.

LeBlanc AK, Atherton M, Bentley RT, et al. VCOG-CTCAE v2 following investigational therapy in dogs and cats. *Vet Comp Oncol*. 2021;19(2):311-352. doi:10.1111/vco.12677.

9. Proprietary Data and Conclusion

ERA operational specifications remain proprietary; staging, pathology, response, safety and event records are maintained under controlled research documentation. All 240 dogs achieved complete response of known oral melanoma within six months, including all dogs with baseline stage IV disease; no melanoma recurrence, metastatic progression or melanoma-related death was documented through 36 months.